The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future

The NETTER-1 study has proven peptide receptor radionuclide therapy (PRRT) to be one of the most effective therapeutic options for metastatic neuroendocrine tumors (NETs), improving progression-free survival and overall survival. However, PRRT response assessment is challenging and no consensus on m...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Virginia Liberini, Martin W. Huellner, Serena Grimaldi, Monica Finessi, Philippe Thuillier, Alfredo Muni, Riccardo E. Pellerito, Mauro G. Papotti, Alessandro Piovesan, Emanuela Arvat, Désirée Deandreis
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	MDPI AG 2020-12-01
Serie:	Diagnostics
Soggetti:	peptide receptor radionuclide therapy PRRT <sup>68</sup>Ga-labeled somatostatin analogue <sup>18</sup>F-FDG response assessment RECIST
Accesso online:	https://www.mdpi.com/2075-4418/10/12/1083
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!